FOXC2 and prostate cancer: Research has shown that FOXC2-AS1 was highly expressed in breast cancer, prostate cancer, and non-small- cell lung cancer (NSCLC); the upregulated expression of FOXC2-AS1 predicted poor survival, and facilitated proliferation and progression of these carcinomas14–16.